Description: Aurinia Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company's lead drug includes Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has a development and license agreement with 3SBio Inc. for the clinical development, registration, and commercialization of voclosporin in China; and licensing and collaboration agreement with Vifor Pharma for the treatment of lupus and various proteinuric nephrology indications. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Home Page: www.auriniapharma.com
AUPH Technical Analysis
4464 Markham Street
Victoria,
BC
V8Z 7X8
Canada
Phone:
250 744 2487
Officers
| Name | Title |
|---|---|
| Mr. Peter S. Greenleaf M.B.A. | Pres, CEO & Director |
| Mr. Joseph M. Miller CPA | Chief Financial Officer |
| Mr. Matthew Maxwell Donley M.B.A. | Exec. VP of Operations & Strategy |
| Mr. Stephen P. Robertson | Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer |
| Ms. DeDe Sheel | VP of Investor Relation |
| Mr. Chris Hays | VP of Marketing |
| Mr. Fran Lynch | VP of Sales |
| Mr. Michael R. Martin | Chief Bus. Officer |
| Ms. Sue Evans | Head of Regulatory Affairs |
| Mr. Scott Habig | Chief Commercial Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 434.7826 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5673 |
| Price-to-Sales TTM: | 4.9298 |
| IPO Date: | 1999-01-26 |
| Fiscal Year End: | December |
| Full Time Employees: | 300 |